Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Esther Kissling*, Mariette Hooiveld, Ivan Martinez-Baz, Clara Mazagatos, Naoma William, Ana Maria Vilcu, Marjolein N. Kooijman, Maja Ilic, Lisa Domegan, Ausenda Machado, Simon De Lusignan, Mihaela Lazar, Adam Meijer, Mia Brytting, Itziar Casado, Amparo Larrauri, Josephine L.K. Murray, Sylvie Behillil, Brechje De Gier, Ivan MlinaricJoan O'Donnell, Ana Paula Rodrigues, Ruby Tsang, Olivia Timnea, Marit de Lange, Maximilian Riess, Jesus Castilla, Francisco Pozo, Mark Hamilton, Alessandra Falchi, Mirjam J. Knol, Sanja Kurecic Filipovic, Linda Dunford, Raquel Guiomar, Jade Cogdale, Carmen Cherciu, Tessa Jansen, Theresa Enkirch, Luca Basile, Jeff Connell, Veronica Gomez, Virginia Sandonis Martin, Sabrina Bacci, Angela M.C. Rose, Lucia Pastore Celentano, Marta Valenciano, I-MOVE-COVID-19 primary care study team

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
4 Downloads (Pure)

Abstract

Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. 

Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. 

Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. 

Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

Original languageEnglish
Article numberA1
Number of pages13
JournalEurosurveillance
Volume27
Issue number21
DOIs
Publication statusPublished - 26 May 2022

Fingerprint

Dive into the research topics of 'Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021'. Together they form a unique fingerprint.

Cite this